<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>v399590_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Amendment
#1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Cooperative
Research and Development Agreement # 02734</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>&ldquo;Cooperative
Research and Development Agreement for the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Development
and Evaluation of the NCI Proprietary Adoptive Cell</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Transfer
Immunotherapy Using Tumor Infiltrating Lymphocytes in</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Patients
with Metastatic Melanoma, Utilizing Genesis Biopharma&rsquo;s</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Business
Development Expertise in Adoptive Cell Transfer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Immunotherapy&rdquo;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purpose of this amendment is to change certain terms of
the above-referenced Cooperative Research and Development Agreement (CRADA). These changes are reflected below, and except for
these changes, all other provisions of the original CRADA remain in full force and effect. Two originals of this amendment are
provided for execution; one is to remain with the National Cancer Institute and the other is to remain with the Collaborator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Collaborator&rsquo;s name is revised from Genesis
Biopharma, Inc. to Lion Biotechnologies, Inc., with accompanying address corrections; the Collaborator Principal Investigator (PI)
is revised from Anthony J. Cataldo to Elma S. Hawkins, Ph.D., M.B.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Appendix A - TIL (tumor infiltrating lymphocytes) for
the following cancer indications are added to the Appendix A Research Plan: bladder, lung, triple-negative breast, and HPV-associated
cancers. Appendix A is also amended for the NCI Surgery Branch to send fresh melanoma, bladder, lung, triple-negative breast, and
HPV-associated cancer tumor specimens collected under NCI protocol 03-C-0277 entitled &ldquo;Cell Harvest and Preparation for Surgery
Branch Adoptive Cell Therapy Protocols&rdquo; to Lion or its agents for performing studies of improved TIL selection and/or for
studies related to TIL scale-out production and process development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Appendix B the Collaborator&rsquo;s yearly funding is
increased to $2,000,000.00 per year, with quarterly payments of $500,000.00 (except for the first payment which is $250,000 prorated
from the amendment execution date to 2/4/15). Appendix B is also amended to add the NCI Surgery Branch&rsquo;s contribution of
melanoma, bladder, lung, triple-negative breast, and HPV-associated cancer specimens to Lion or its agents for studies under this
CRADA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5) Appendix C &mdash; Section 8.8 and a definition for &ldquo;Multi-Party
Data&rdquo; is added, along with accompanying revisions to Section 7.2 and 7.6 licensing provisions; Section 13.9 is revised to
add language relating to the use of Collaborator&rsquo;s agents, contractors or consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>SIGNATURES
BEGIN ON THE NEXT PAGE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%">ACCEPTED AND AGREED TO:</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">For the National Cancer Institute</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ JAMES H. DOROSHOW</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">1/16/2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">James H. Doroshow, M.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Deputy Director for Clinical and Translational</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Research, NCI</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">For Collaborator:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ ELMA S. HAWKINS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">1/22/2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Elma S. Hawkins, Ph.D., M.B.A.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>PUBLIC
HEALTH SERVICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>FOR INTRAMURAL-PHS
CLINICAL RESEARCH</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement is based on the model Cooperative Research and
Development Agreement (&ldquo;CRADA&rdquo;) adopted by the U.S. Public Health Service (&ldquo;PHS&rdquo;) Technology Transfer Policy
Board for use by components of the National Institutes of Health (&ldquo;NIH&rdquo;), the Centers for Disease Control and Prevention
(&ldquo;CDC&rdquo;), and the Food and Drug Administration (&ldquo;FDA&rdquo;), which are agencies of the PHS within the Department
of Health and Human Services (&ldquo;HHS&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Cover Page identifies the Parties to this CRADA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The U.S. Department of Health and Human
Services, as represented by the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>National Cancer Institute</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">an Institute, Center, or Division (hereinafter
referred to as the &ldquo;<B>IC</B>&rdquo;) of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>National Institutes of Health</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Lion Biotechnologies, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">hereinafter referred to as the &ldquo;<B>Collaborator</B>&rdquo;,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">having offices at <B>21900 Burbank Blvd.,
3<SUP>rd</SUP> Floor, Woodland Hills, CA 91367</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">created and operating under the laws of
Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 34%; text-align: center; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CRADA
    Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Page 1 of 15</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">CONTACTS
INFORMATION PAGE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CRADA Notices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">For ICD:</TD>
    <TD STYLE="width: 50%">For Collaborator:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Technology Transfer Center, NCI</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Lion Biotechnologies, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">6120 Executive Blvd., Suite 450 </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">21900 Burbank Blvd., 3<SUP>rd</SUP> Floor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Rockville, MD&nbsp;&nbsp;20852</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Woodland Hills, CA&nbsp;&nbsp;91367</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Tel.&nbsp;&nbsp;301-496-0477</TD>
    <TD STYLE="text-align: justify">Tel.&nbsp;&nbsp;818-992-3126</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Fax: 301-402-2117</TD>
    <TD STYLE="text-align: justify">www.lionbio.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Patenting and Licensing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">For ICD:</TD>
    <TD STYLE="width: 50%">For Collaborator (if separate from above):</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Division Director, Division of Technology</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Peter D. Ho, Ph.D., M.B.A.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in">Development and Transfer</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Director, Business Development</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>NIH Office of Technology Transfer</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Lion Biotechnologies, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>6011 Executive Boulevard, Suite 325</TD>
    <TD STYLE="border-bottom: Black 1pt solid">21900 Burbank Blvd., 3<SUP>rd</SUP> Floor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Rockville, Maryland 20852-3804</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Woodland Hills, CA&nbsp;&nbsp;91367</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Tel:&nbsp;&nbsp;301-496-7057</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Tel.&nbsp;&nbsp;818-992-3126</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Fax:&nbsp;&nbsp;301-402-0220</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: -3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delivery of Materials Identified In Appendix
B (if any)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">For ICD:</TD>
    <TD STYLE="width: 50%">For Collaborator:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Steven A. Rosenberg, M.D., Ph.D.</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Elma S. Hawkins, Ph.D., M.B.A.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Surgery Branch, NCI</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Clinical Development</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10 Center Drive, MSC 1201</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Lion Biotechnologies, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Bldg. 10, CRC Room 3-3940</TD>
    <TD STYLE="border-bottom: Black 1pt solid">21900 Burbank Blvd., 3<SUP>rd</SUP> Floor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Bethesda, MD&nbsp;&nbsp;20892-1201</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Woodland Hills, CA&nbsp;&nbsp;91367</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Tel. 301-496-4164</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Tel.&nbsp;&nbsp;646-775-4817</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Fax: 301-402-1738</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt">CRADA Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font-size: 10pt">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Page 2 of 15</FONT></TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">SUMMARY PAGE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION
OR PERMISSION, </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>RELEASE THIS SUMMARY PAGE TO THE PUBLIC.
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in">TITLE OF CRADA:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooperative
Research and Development Agreement for the Development and Evaluation of the NCI Proprietary Adoptive Cell Transfer Immunotherapy
Using Tumor Infiltrating Lymphocytes in Patients with Metastatic Melanoma, Bladder, Lung, Triple-negative Breast, and HPV-associated
Cancers, Utilizing Lion Biotechnologies&rsquo; Business Development Expertise in Adoptive Cell Transfer Immunotherapy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">PHS [IC] Component:</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">National Cancer Institute</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>IC CRADA Principal Investigator:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Steven A. Rosenberg, M.D., Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Collaborator:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Lion Biotechnologies, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Collaborator CRADA Principal Investigator:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Elma S. Hawkins, Ph.D., M.B.A.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Term of CRADA:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Five (5) years from the Effective Date</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: -3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ABSTRACT OF THE RESEARCH PLAN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The principal goal of this CRADA is to develop and evaluate
effective adoptive cell transfer-based immunotherapies (ACT) using Tumor Infiltrating Lymphocytes (TIL), where the ACT/TIL therapy
approach is proprietary to the NCI, for the treatment of patients with metastatic melanoma, bladder, lung, triple-negative breast,
and HPV-associated cancers, utilizing the business development expertise and resources of Lion Biotechnologies, Inc., Specifically
this CRADA will (1) support the <I>in vitro</I> development of improved methods for the large scale generation and selection of
TIL with anti-tumor reactivity from patients with metastatic melanoma, bladder, lung, triple-negative breast, and HPV-associated
cancers, based on ACT therapies developed by and proprietary to the NCI Surgery Branch, to be used for large scale production of
TIL for the ACT treatment of patients with these cancers; (2) develop these approaches for large scale TIL generation that are
in accord with Good Manufacturing Practice (GMP) procedures suitable for use in treating patients with metastatic melanoma, bladder,
lung, triple-negative breast, and HPV-associated cancers; and (3) develop clinical trials using these improved methods of large
scale TIL generation as well as improved patient preparative regimens with the goal of commercializing the ACT/TIL therapy approach
for treating patients with metastatic melanoma, bladder, lung, triple-negative breast, and HPV-associated cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CRADA Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Page 3 of 15</FONT></TD>
    <TD></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PUBLIC HEALTH SERVICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COOPERATIVE RESEARCH AND DEVELOPMENT
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR INTRAMURAL-PHS CLINICAL RESEARCH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RESEARCH PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Title of CRADA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cooperative Research and Development Agreement
for the Development and Evaluation of the NCI Proprietary Adoptive Cell Transfer Immunotherapy Using Tumor Infiltrating Lymphocytes
in Patients with Metastatic Melanoma, Bladder, Lung, Triple-negative Breast, and HPV-associated Cancers<U>,</U> Utilizing Lion
Biotechnologies, Inc.&rsquo;s Business Development Expertise in Adoptive Cell Transfer Immunotherapy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NCI Principal Investigator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Steven A. Rosenberg, M.D., Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief, Surgery Branch</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Center for Cancer Research (CCR)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">National Cancer Institute (NCI)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Collaborator Principal Investigator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Elma S. Hawkins, Ph.D., M.B.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Operating Officer, Clinical Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Lion Biotechnologies, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Term of CRADA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Five (5) years from the date of the final
CRADA signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">_____________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Goals
of this CRADA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The principal goal of this CRADA is to develop and evaluate
effective adoptive cell transfer-based immunotherapies (ACT) using Tumor Infiltrating Lymphocytes (TIL), where the ACT/TIL therapy
approach is proprietary to the NCI, for the treatment of patients with metastatic melanoma, bladder, lung, triple-negative breast,
and HPV (Human Papilloma Virus)-associated cancers, utilizing the business development expertise and resources of Lion Biotechnologies,
Inc., Specifically this CRADA will (1) support the <I>in vitro</I> development of improved methods for the large scale generation
and selection of TIL with anti-tumor reactivity from patients with metastatic melanoma, bladder, lung, triple-negative breast,
and HPV-associated cancers, based on ACT therapies developed by and proprietary to the NCI Surgery Branch, to be used for large
scale production of TIL for the ACT treatment of patients with these cancers; (2) develop these approaches for large scale TIL
generation that are in accord with Good Manufacturing Practice (GMP) procedures suitable for use in treating patients with metastatic
melanoma, bladder, lung, triple-negative breast, and HPV-associated cancers; and (3) develop clinical trials using these improved
methods of large scale TIL generation as well as improved patient preparative regimens with the goal of commercializing the ACT/TIL
therapy approach for treating patients with metastatic melanoma, bladder, lung, triple-negative breast, and HPV-associated cancers.
The scope of this CRADA, including any <I>in vitro</I> and <I>in vivo</I> testing conducted by Dr. Steven A. Rosenberg and members
of the NCI Surgery Branch within the CCR is strictly limited to the development of TIL as a single agent therapy in conjunction
with commercially available reagents routinely used for ACT therapy (aldesleukin (IL-2), other chemotherapeutic agents) in treating
patients with metastatic melanoma, bladder, lung, triple-negative breast, and HPV-associated cancers, utilizing Lion&rsquo;s expertise
in the large scale production of adoptive cell transfer immunotherapies. Additional research or clinical activities involving current
or prospective NCI Surgery Branch adoptive immunotherapy protocols are outside the scope of this CRADA unless and until the Parties
mutually agree to these studies which shall be added by written amendment to this CRADA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CRADA Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Page 4 of 15</FONT></TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Confidential</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Expertise
of the Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Steven A. Rosenberg has extensive experience in the development
and application of his proprietary adoptive cell-based therapies (ACT) for patients with cancer. His laboratory has developed <I>in
vitro</I> techniques for generating anti-tumor T cells obtained from patient tumors (TIL) under conditions suitable for subsequent
infusion. Dr. Rosenberg and his colleagues in the NCI Surgery Branch have extensive experience in the development of cell-based
reagents and the conduct of clinical trials utilizing these cells in immunotherapeutic protocols.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lion Biotechnologies, Inc. has assembled a team of senior level
scientists and clinicians who have experience in the application of cell-based immunotherapies to help guide the commercial development
of ACT therapy for the treatment of metastatic melanoma, bladder, lung, triple-negative breast, and HPV-associated cancers, as
specified in &ldquo;Goals of this CRADA&rdquo; (&ldquo;Goals&rdquo;) based on the NCI Surgery Branch proprietary technologies for
TIL preparation and administration of ACT to patients. Lion is developing GMP facilities to perform this work emphasizing the development
and evaluation of improved techniques for TIL generation that meet GMP standards as well as to conduct clinical trials of ACT/TIL
therapy designed to meet the standards of the FDA to achieve approval for the commercialization of this treatment approach. Thus
the combination of the scientific and clinical expertise of the NCI Surgery Branch with the scientific and clinical expertise of
Lion, and availability of Lion&rsquo;s GMP production facilities, represents an ideal opportunity that can lead to the commercialization
of the ACT/TIL treatment approach for patients with those cancers as specified in &ldquo;Goals&rdquo;, making these treatments
more widely available to patients in need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The NCI Surgery Branch and Lion thus have complementary expertise
and facilities that can develop technologies and clinical treatment approaches that have the potential to improve cell transfer
therapy and make it more widely available to patients through commercialization by Lion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CRADA Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Page 5 of 15</FONT></TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Experimental
Plan </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The experimental details that follow are approximate and may
be changed upon mutual agreement of the NCI and Collaborator. Any change in the scope of this CRADA will be by mutual consent and
written Amendment to the CRADA.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Develop
improved methods for the generation and selection of TIL with anti-tumor reactivity from patients with metastatic melanoma, bladder,
lung, triple-negative breast, and HPV-associated cancers, as specified in &ldquo;Goals&rdquo;,</B> <B> based on adoptive cell transfer
therapies proprietary to and developed by the NCI Surgery Branch, for use in the large scale production of TIL for this ACT treatment
of these cancers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Simplified and better methods
for TIL selection and growth are needed to supplement current NCI Surgery Branch efforts in order to expand ACT/TIL therapy to
greater numbers of patients with those cancers as specified in &ldquo;Goals&rdquo;, Studies of improved methods for TIL selection
will be investigated by the NCI Surgery Branch and Lion. This will include use of <I>in vitro</I> assays of specificity that are
based on specific blocking of Class I MHC (Major Histocompatibility Complex) molecules that can provide evidence for the specific
recognition of autologous tumor and use of sensitive assays of the upregulation of molecules such as 4-1-BB or others on the lymphocyte
cell surface. Such studies in the NCI Surgery Branch may also include the separation of phenotypically different lymphocyte subsets
present in TIL such as central memory, effector memory and terminally differentiated effector cells. NCI Surgery Branch studies
in mice have shown that lymphocyte subsets such as central memory cells can be more effective in the adoptive immunotherapy of
experimental tumors and this needs to be studied in humans with those cancers as specified in &ldquo;Goals.&rdquo; In addition,
NCI Surgery Branch may send fresh melanoma, bladder, lung, triple-negative breast, and HPV-associated cancer specimens from NCI
protocol 03-C-0277 entitled &ldquo;Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols&rdquo; to Lion
or its agents to develop techniques for growing TIL and for performing assays involving criteria which are designed to improve
TIL selection. Assays will be performed on the growing TIL to evaluate their recognition of autologous tumor cells assessed by
gamma interferon release in overnight co-culture with tumor and to evaluate the phenotypic expression of cell surface markers on
TIL such as CD62L, CD45RO, CD45RA and CD127. Such studies would form the basis for TIL selection and generation for use in the
large scale production of TIL for the treatment of patients with those cancers as specified in &ldquo;Goals.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>II.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Develop
approaches to large scale TIL generation that are in accord with Good Manufacturing Practice (GMP) procedures suitable for their
use in treating patients with metastatic melanoma, </B>bladder, lung, triple-negative breast, and HPV-associated cancers, as specified
in &ldquo;Goals&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CRADA Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Page 6 of 15</FONT></TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The selection and growth of autologous
TIL from patients with those cancers as specified in &ldquo;Goals&rdquo; is a vital part of the successful use of this approach.
Prior NCI Surgery Branch methods for TIL growth involved extensive <I>in vitro</I> testing using multiple cell lines and fresh
tissue samples as well as the growth of cells in up to 40 2-liter culture bags using large amounts of medium to treat each patient.
Under this CRADA, studies will be conducted of improved methods for the generation of the large numbers of TIL necessary for patient
treatment. These studies will explore the use of alternate culture vessels including those that involve the use of gas permeable
membranes. The NCI Surgery Branch has begun some of these studies but extensive additional studies are required to optimize cell
growth including the determination of the best concentrations of feeder cells, timing of media change and concentrations of growth
factors such as IL-2 (commercially available). These studies will be conducted by the NCI Surgery Branch with advice, input and
expertise provided by Lion.<B> </B>In addition, the NCI Surgery Branch may send tumor samples from those cancers as specified in
&ldquo;Goals&rdquo; which were collected from NCI protocol 03-C-0277 to Lion or its agents for studies including scale-out for
the methods of expansion of individualized lymphocyte treatments, assays for product and in-process performance, and harmonization
assays for centralized process development and determination of TIL product consistency. Additionally, biological reagents and
materials may be sent to Lion or its agents for the development of qualifying assays and process development related to scale-out
of the TIL expansion process. Techniques thus described will need to be adapted to meet the GMP requirements of the Food and Drug
Administration for infusion into patients. This may require modification of the procedures developed in the NCI Surgery Branch.
Lion and the NCI Surgery Branch will work together to develop Standard Operating Procedures (SOP) for large scale TIL growth, selection
and testing that meet the approval of the FDA. Joint meetings with the FDA will be required to define the exact format and criteria
need to meet FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>III.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Develop
clinical trials using these improved methods of large scale TIL generation as well as improved patient preparative regimens to
treat patients with metastatic melanoma</B>,<B> bladder, lung, triple-negative breast and HPV-associated cancers, as specified
in &ldquo;Goals&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Clinical trials will be designed and implemented to
evaluate the clinical effectiveness of ACT/TIL therapy resulting from large scale techniques in patients with those cancers as
specified in &ldquo;Goals&rdquo;, based on the proprietary NCI Surgery Branch technology and approaches developed in the first
two parts of this Experimental Plan. Lion and the NCI Surgery Branch will work together to develop multiinstitutional clinical
trials evaluating the clinical effectiveness of the administration of autologous TIL generated using Lion technology to patients
with those cancers as specified in &ldquo;Goals&rdquo; that can potentially be used as licensing trials for FDA approval. The NCI
Surgery Branch does not have a suitable GMP facility that will meet FDA standards for the conduct of such a trial. Exploratory
pilot trials may be necessary prior to beginning a licensing trial and these may be conducted in the Surgery Branch alone or in
conjunction with other multicenter sites associated with Lion. The development and conduct of licensing trials will require the
GMP expertise of Lion and the extensive experience of the NCI Surgery Branch working together. TIL for these trials will be produced
on a large scale by Lion at a central facility for distribution to participating multicenter sites (including the NCI Surgery Branch).
An IND with the FDA will be filed by Lion which will serve as the Coordinating Center for such trials. The goal of such trials
will be to generate data to support the approval by the FDA of this ACT/TIL therapy approach. <I>In vitro</I> testing of patient
samples from such trials will evaluate the activity and persistence level of the transferred cells in the circulation of treated
patients and will be conducted by the NCI Surgery Branch both for any pilot trials that are performed as well as for the large
multiinstitutional trials that are planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CRADA Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Page 7 of 15</FONT></TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps"><B>Description
of the Contributions and Responsibilities of the Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><B>Surgery Branch, NCI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">-</TD><TD>Develop and test new improved and simplified <I>in vitro</I> methods for the selection and growth of TIL with anti-tumor activity
for large scale preparations that can be used in clinical cell transfer studies. As described in the Experimental Plan above, this
will include evaluation of new growth techniques, culture vessels, and tests</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 31.5pt">-</TD><TD>Perform <I>in vitro</I> studies of the immunologic parameters surrounding the new cell transfer clinical protocol(s) by analyzing
the phenotypic and functional properties of the transferred cells and their persistence in the patient following adoptive transfer
in all clinical trials conducted under this CRADA, as outlined in Section III above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><B>Lion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">-</TD><TD>Develop, implement and evaluate<B> </B>GMP procedures for the large scale production of TIL suitable for infusion into p<B>a</B>tients
with metastatic melanoma, bladder, lung, triple-negative breast, and HPV-associated cancers as specified in &ldquo;Goals.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">-</TD><TD>Conduct studies including scale-out for the methods of expansion of individualized lymphocyte treatments, assays for product
and in-process performance, and harmonization assays for centralized process development and determination of TIL product consistency.
Additional studies may be conducted for the development of qualifying assays and process development related to scale-out of the
TIL expansion process.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">-</TD><TD>Consult with the FDA to determine the appropriate clinical trial design necessary to secure approval for the commercial development
of TIL therapy for patients with those cancers as specified in &ldquo;Goals&rdquo; and sponsor the IND for these new clinical protocols
Serve as the coordinating center for the multicenter licensing clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">-</TD><TD>Supply TIL in sufficient quantities to the NCI Surgery Branch and other multicenter sites to complete the planned clinical
trials (including the licensing trial) needed for FDA approval of ACT/TIL. Support the establishment of a central facility for
the processing and provision of TIL for the studies under this CRADA.</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CRADA Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Page 8 of 15</FONT></TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"></P>
<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: center"><B>Surgery Branch, NCI and Lion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">-</TD>
    <TD STYLE="width: 90%">Develop SOP for large scale TIL growth, selection and testing to support the FDA approval of the ACT/TIL therapy approach.&nbsp;&nbsp;Attend joint meetings with the FDA to define the exact format and criteria needed in the clinical trial(s) to obtain FDA approval.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Develop, conduct and evaluate multiinstitutional clinical trials (to include the NCI Surgery Branch as a clinical trial site) for patients with metastatic melanoma, bladder, lung, triple-negative breast and HPV-associated cancers (as specified in&rdquo;Goals&rdquo;) treated with TIL that can be used as licensing trials required for FDA approval and subsequent commercialization of ACT/TIL.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>-</TD>
    <TD>Conduct assays to be used in the selection of appropriate cells (based on both functional and phenotypic criteria) to optimize the effectiveness of the adoptive transfer<B>. </B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>-</TD>
    <TD>Exchange information and expertise to further the successful development of TIL therapy for patients with those cancers as specified in &ldquo;Goals.&rdquo;&nbsp;&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Related NCI and Collaborator
Agreements: </B>None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Related Intellectual
Property and Business/Scientific Expertise of the Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>NCI Surgery Branch</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1) PCT/US03/27873 entitled &ldquo;Immunotherapy with
<I>In Vitro</I>-Selected Antigen-specific Lymphocytes After Nonmyeloablative Lymphodepleting Chemotherapy&ldquo;, filed 9/5/03.
Inventors: Mark E. Dudley, Steven A. Rosenberg, John R. Wunderlich. This is inclusive of all U.S. continuing applications and divisionals,
and foreign applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">2) USSN 12/869,390 entitled &ldquo;Adoptive Cell Therapy
with Young T Cells&rdquo;, filed 8/26/10. Inventors: Mark E. Dudley and Steven A. Rosenberg. This is inclusive of all U.S. continuing
applications and divisionals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">3)  PCT/US12/02974 entitled &ldquo;Methods of Growing
Tumor Infiltrating Lymphocytes in Gas-Permeable Containers&rdquo;, filed 3/20/12. Inventors: Steven A. Rosenberg, Mark E. Dudley,
et al.. This is inclusive of all U.S. continuing applications and divisionals, and foreign applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt">Case Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font-size: 10pt">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Page 9 of 15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">4) PCT/US14/046478 entitled &ldquo;Methods of Preparing
Anti-human Papillomavirus Antigen T Cells&rdquo;, filed 7/14/2014. Inventors: Christian S. Hinrichs and Steven A. Rosenberg. This
is inclusive of all U.S. continuing applications and divisionals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Lion Biotechnologies, Inc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lion has applied to NIH for a license to NIH owned intellectual
property under the license applicationsA-079-2014 and A-286-2014; Lion has a license to NIH-owned intellectual property under license
L-129-2011/0. Collaborator desires to license NIH owned intellectual property that includes the patents describing the NCI proprietary
ACT/TIL therapy approach to be developed under this CRADA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lion Biotechnologies, Inc. is a publicly traded biotechnology
company developing therapies for the treatment of cancer. Lion&rsquo;s lead therapeutic candidate will be an autologous cell therapy
product using tumor infiltrating lymphocytes for the treatment of metastatic melanoma, bladder, lung, triple-negative breast and
HPV-associated cancers as specified in&rdquo;Goals&rdquo;, to be developed under this CRADA. Lion has a partnership with a major
manufacturer for the provision of TIL for clinical trials to be conducted under this CRADA as well as post-regulatory approval.
The manufacturing facility is cGMP certified and inspected by FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt">Case Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font-size: 10pt">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Page 10 of 15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PUBLIC HEALTH SERVICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COOPERATIVE RESEARCH AND DEVELOPMENT
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR INTRAMURAL-PHS CLINICAL RESEARCH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STAFFING, FUNDING AND MATERIALS/EQUIPMENT
CONTRIBUTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Staffing Contributions:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IC will provide scientific staff and other support necessary
to conduct the research and other activities described in the Research Plan. IC&rsquo;s scientific staff will include IC&rsquo;s
CRADA Principal Investigator and technical staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IC estimates that <U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;3-5&#9;&nbsp;&nbsp;&nbsp;</U> person-years of effort
per year will be required to complete the CRADA research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Collaborator will provide scientific staff and other support
necessary to conduct the research and other activities described in the Research Plan. Collaborator&rsquo;s scientific staff will
include Collaborator&rsquo;s Principal Investigator and technical staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Collaborator estimates that <U>&#9;&nbsp;&nbsp;&nbsp;3-5&nbsp;&nbsp;&nbsp;&#9;</U> person-years
of effort per year will be required to complete the CRADA research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Funding Contributions:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Collaborator agrees to provide funds in the amount of $2,000,000.00
per year of the CRADA for IC to use to acquire technical, statistical, and administrative support for the research activities,
as well as to pay for supplies and travel expenses. Collaborator will provide funds in the amount of $500,000.00 on a quarterly
basis. The first quarterly installment of of a prorated amount of $250,000.00 from the Amendment execution date to February 4,
2015 will be due within thirty (30) days of the Effective Date of the Amendment. Each subsequent installment will be due within
thirty (30) days of each quarterly anniversary of the CRADA Effective Date. Collaborator agrees that IC can allocate the funding
between the various categories in support of the CRADA research as IC&rsquo;s CRADA PI sees fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CRADA PAYMENTS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Collaborator will make checks payable to the National Cancer
Institute and will reference the CRADA number 02734 and title &ldquo;CRADA for the Development and Evaluation of the NCI Proprietary
Adoptive Cell Transfer Immunotherapy Using Tumor Infiltrating Lymphocytes in Patients with Metastatic Melanoma, Bladder, Lung,
Triple-negative Breast and HPV-associated Cancers Utilizing Lion Biotechnologies, Inc.&rsquo;s Business Development Expertise in
Adoptive Cell Transfer Immunotherapy&rdquo; on each check,<U> </U>and will send them via trackable mail or courier to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt">Case Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font-size: 10pt">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Page 11 of 15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CRADA Funds Coordinator</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Technology Transfer Center, NCI</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6120 Executive Blvd., Suite 450</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockville, MD 20852</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CRADA Travel Payments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Travel arrangements for all Government staff will be made in
accordance with the Federal Travel Rules and Regulations, whether arranged by IC and funded using either appropriated funds or
CRADA funds, or arranged and funded directly by Collaborator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Materials/Equipment Contributions:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IC will provide the following IC Materials for use under this
CRADA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">Test Article:</TD>
    <TD STYLE="width: 60%">None</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>IC Materials:</TD>
    <TD>Fresh melanoma, bladder cancer, lung cancer, triple- negative breast cancer, and HPV-associated cancer tumor specimens collected under NCI protocol &nbsp;03-C-0277 entitled &ldquo;Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Capital Equipment:</TD>
    <TD>None</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Collaborator will provide the following Collaborator Materials
and/or capital equipment for use under this CRADA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">Test Article:</TD>
    <TD STYLE="width: 60%">Autologous Tumor Infiltrating Lymphocytes (TIL) grown</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>and processed under GMP conditions, suitable for use in clinical trials under this CRADA.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Collaborator Materials:</TD>
    <TD>None</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Capital Equipment:</TD>
    <TD>None</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If either Party decides to provide additional Materials for
use under this CRADA, those materials will be transferred under a cover letter that identifies them and states that they are being
provided under the terms of the CRADA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt">Case Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font-size: 10pt">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Page 12 of 15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PUBLIC HEALTH SERVICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COOPERATIVE RESEARCH AND DEVELOPMENT
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR INTRAMURAL-PHS CLINICAL RESEARCH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MODIFICATIONS TO THE MODEL CRADA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Add the Definition of &ldquo;Multi-Party Data&rdquo; in Article
2 </B>to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Multi-Party Data&rdquo;</B> means
data from studies sponsored by IC pursuant to Clinical Trial Agreements (CTA) or CRADAs, where such data are collected under Protocols
involving combinations of investigational agents supplied from more than one CTA or CRADA collaborator. &ldquo;Multi-Party Data&rdquo;
also means data from studies where such data are collected pursuant to research involving combinations of proprietary materials
from more than one collaborator as documented in more than one agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Amend Section 7.2</B> to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">7.2&#9;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaborator&rsquo;s License Option to CRADA
Subject Inventions</B>. With respect to Government rights to any CRADA Subject Invention made solely by an IC employee(s) or made
jointly by an IC employee(s) and a Collaborator employee(s) for which a Patent Application was filed, PHS hereby grants to Collaborator
an exclusive option to elect an exclusive or nonexclusive or co-exclusive, if applicable, commercialization license. The option
to elect a co-exclusive license shall apply when a CRADA Subject Invention is also an Invention made under another agreement resulting
from mutually agreed upon studies, as described in Section 8.8 (regarding Multi-Party Data Rights)], and the field of use of this
co-exclusive license shall be limited to the use of the combination of the Test Article with another agent(s) commensurate with
the scope of the Research Plan. The license will be substantially in the form of the appropriate model PHS license agreement and
will fairly reflect the nature of the CRADA Subject Invention, the relative contributions of the Parties to the CRADA Subject Invention
and the CRADA, a plan for the development and marketing of the CRADA Subject Invention, the risks incurred by Collaborator, and
the costs of subsequent research and development needed to bring the CRADA Subject Invention to the marketplace. The field of use
of the license will not exceed the scope of the Research Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="text-align: center; width: 33%"><FONT STYLE="font-size: 10pt">Case Ref. No. 02734</FONT></TD>
    <TD STYLE="text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Page 13 of 15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Amend Section 7.6</B> to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">7.6<B>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third Party License</B>. Pursuant to 15
U.S.C. &sect; 3710a(b)(1)(B), if PHS grants Collaborator an exclusive license or co-exclusive license to a CRADA Subject Invention
made solely by an IC employee or jointly with a Collaborator employee, the Government will retain the right to require Collaborator
to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the CRADA Subject Invention
in Collaborator&rsquo;s licensed field of use on terms that are reasonable under the circumstances; or, if Collaborator fails to
grant a license, to grant a license itself. The exercise of these rights by the Government will only be in exceptional circumstances
and only if the Government determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied
by Collaborator, (ii) the action is necessary to meet requirements for public use specified by federal regulations, and such requirements
are not reasonably satisfied by Collaborator; or (iii) Collaborator has failed to comply with an agreement containing provisions
described in 15 U.S.C. &sect; 3710a(c)(4)(B). The</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">determination made by the Government under this Paragraph
is subject to administrative</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">appeal and judicial review under 35 U.S.C. &sect;
203(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 7.8 &ldquo;Joint CRADA Subject
Inventions Not Exclusively Licensed by Collaborator</B>&rdquo; is deleted in its entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Add Section 8.8</B> as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.8&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Multi-Party Data Rights.</B>
For mutually agreed upon clinical Protocol(s) where Test Article is used in combination with another investigational agent supplied
to IC pursuant to a CTA or CRADA between IC and an entity not a Party to this CRADA (hereinafter referred to as &ldquo;Third Party&rdquo;),
or for non-clinical study(ies) where research involving combinations of proprietary materials from more than one collaborator as
documented in more than one agreement, the access and use of Multi-Party Data by the Collaborator and Third Party shall be co-exclusive
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.8.1</TD><TD>IC will provide both Collaborator and Third Party with notice regarding the existence and nature of the agreements governing
the use of the Test Article and Third Party&rsquo;s investigational agent, the design of the proposed combination Protocol(s) or
non-clinical study(ies), and the existence of any obligations that might restrict IC&rsquo;s participation in the proposed combination
Protocols or non-clinical study(ies).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.8.2</TD><TD STYLE="text-align: justify">Collaborator shall agree to permit use of the Multi-Party Data from these trials by Third Party
to the extent necessary to allow Third Party to develop, obtain regulatory approval for, or commercialize its own investigational
agent(s). However, this provision will not apply unless Third Party also agrees to Collaborator&rsquo;s reciprocal use of Multi-Party
Data.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.8.3</TD><TD STYLE="text-align: justify">Collaborator and Third Party must agree in writing prior to the commencement of the combination
Protocol(s) or non-clinical study(ies) that each will use the Multi-Party Data solely for the development, regulatory approval,
and commercialization of its own investigational agent(s).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt">Case Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font-size: 10pt">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Page 14 of 15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.84</TD><TD STYLE="text-align: justify">The sharing of Multi-Party Data does not alter the ownership of the Multi-Party Data or obligations
of IC, Collaborator and Third Party to keep Confidential Information owned by any other Party or Parties confidential.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amend the Definition of &ldquo;Independent Contractors&rdquo;
in Article 13.9 </B>to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13.9&#9;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Independent Contractors</B>. The relationship of
the Parties to this CRADA is that of independent contractors and not agents of each other or joint venturers or partners. Each
Party shall maintain sole and exclusive control over its personnel and operations. If Collaborator elects to perform any portion
of the Research Plan through an agent, contractor or consultant, Collaborator agrees to incorporate into such contracts all provisions
necessary to ensure that the work of such agents, contractors or consultants is governed by the terms of the CRADA, including,
but not limited to a provision for the assignment of inventions of the agent, contractor or consultant to the Collaborator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">PHS ICT-CRADA</FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt">Case Ref. No. 02734</FONT></TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font-size: 10pt">MODEL ADOPTED June 18, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Page 15 of 15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B><I>Confidential</I></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
